As part of major organic initiatives by market participants, a rising pipeline product will be developed into a new vaccine product. For example, in 2017, the MHRA approved Seqirus’ FLAUD, the first and only adjuvant-based trivalent influenza vaccine, against influenza virus in the elderly (adults aged 65 and above). In the same year, Seqirus launched its influenza vaccine portfolio in the United States, with over 50 million doses for protection against seasonal influenza in 2017-2018.
A comprehensive study on the impact of the Covid-19 pandemic on the global Influenza Vaccines Market is also crafted in the report. Impact analysis covers a wide range of factors including supply chain analysis, market expansion, major restraining factors, and future growth during the pandemic. This will enable the investor/user to better understand the overall picture of the market and make decisions that will be favorable to streamline the business.
Get Sample Report with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/1705
The portfolio includes FLAUD, FLUCELVAX QUADRIVALENT, AFLURIA QUADRIVALENT, AFLURIA, and FLUVIRIN. Moreover, in 2017, FluGen, Inc., received US$ 14.4 million by Department of Defense for evaluating Universal Flu Vaccine, RedeeFlu, of Mismatched Strains. In Sep 2017, Novavax initiating phase1/2 clinical trials for nanoparticle seasonal influenza vaccine in older adults. In April 2018, BiodVax Pharmaceuticals LTD., started enrollment of patients for phase 2 clinical trials for universal flu vaccine candidate, M-001.
The rising incidence of seasonal influenza in the paediatric population is driving demand for novel vaccinations. Influenza is thought to affect between 5% and 10% of adults, as well as 20 to 30% of children. Furthermore, firms are working to close the gap between demand and supply by developing vaccines using cutting-edge technologies such as egg-based, cell-based, and recombinant-based products. . Furthermore, market growth is aided by increased awareness and measures to boost vaccine coverage. The Advisory Committee on Immunization Practices (ACIP) recommends routine annual influenza vaccination for everyone over the age of six months in its 2017–2018 recommendations guidelines. However, the high cost of vaccine development is projected to stifle market expansion in the future.
Key takeaways of the Influenza Vaccines Market:
The global influenza vaccines market is expected to expand at a CAGR of 4.4% during the forecast period (2018 – 2026), owing to increasing R&D activities of market players.
Trivalent vaccine is expected to dominate vaccine type segment, owing to more number of products
Influenza type A virus segment is expected to be predominant, owing to increasing prevalence of type A based infection
Pediatric being more susceptible to influenza virus is expected to lead age group segment
Some of the major players involved in global influenza vaccines market include Seqirus Vaccines Limited, GlaxoSmithKline plc
Want to “ahead” with your competiors request a PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/1705
Reasons to Purchase this Report
• Current and future of global Influenza Vaccines market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Vaccine Type
- Market Snippet, By Virus Type
- Market Snippet, By Age Group
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Industry Trends
- Pipeline Products
- Regulatory Scenario
- Epidemiology
- PEST Analysis
- PORTER’S Five Forces
- Market Dynamics
- Global Influenza Vaccine Market, By Vaccine Type, 2016 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Trivalent Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
- Quadrivalent Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
- Introduction
- Global Influenza Vaccine Market, By Virus Type, 2016–2026, (US$ Million)
- Introduction
- Market Share Analysis, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Influenza Virus Type A
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
- Influenza Virus Type B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
- Introduction
- Global Influenza Vaccine Market, By Age Group, 2016–2026, (US$ Million)
- Introduction
- Market Share Analysis, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
- Introduction
- Global Influenza Vaccine Market, By Region, 2016–2026, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2026
- Regional Trends
- North America
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2026, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- Northern Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Seqirus Vaccines Limited*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Market Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Market Strategies
- ID Biomedical Corporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Market Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Market Strategies
- Protein Sciences Corp.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Market Strategies
- MedImmune LLC
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Market Strategies
- Seqirus Vaccines Limited*
- Analyst Views
- Section
- References
- Research Methodology
- About Us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837